Motus gi announces enrollment of patients at second site in the european union outpatient study of the pure-vu® system

Fort lauderdale, fla., sept. 08, 2021 (globe newswire) -- motus gi holdings, inc., (nasdaq: mots) ("motus gi" or the "company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, today announced that gastrozentrum lippe, one of the top private endoscopy clinics in germany, has enrolled patients into the european union (eu) outpatient study of the pure-vu system, which is evaluating the clinical outcomes in patients with a history of poor bowel preparation using a low volume preparation with limited diet restrictions and the pure-vu system. the study was initiated in mid-june 2021 with patients at the radboud university medical center (netherlands).
MOTS Ratings Summary
MOTS Quant Ranking